Scarica l'app Stockscreener
1.77
3.28%
-0.06
Dopo l'orario di chiusura:
1.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Precedente Chiudi:
$1.83
Aprire:
$1.82
Volume 24 ore:
573.32K
Relative Volume:
0.70
Capitalizzazione di mercato:
$188.69M
Reddito:
$45.44M
Utile/perdita netta:
$-35.43M
Rapporto P/E:
-5.2059
EPS:
-0.34
Flusso di cassa netto:
$-25.39M
1 W Prestazione:
+9.26%
1M Prestazione:
+19.59%
6M Prestazione:
-30.59%
1 anno Prestazione:
-54.03%
Intervallo 1D:
$1.755
$1.865
Intervallo di 1 settimana:
$1.515
$1.865
Portata 52W:
$1.26
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Nome
Maxcyte Inc
Settore
Industria
Telefono
301-517-5556
Indirizzo
9713 KEY WEST AVENUE,, ROCKVILLE
Confronta MXCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.77 | 175.90M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
127.63 | 231.95B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
97.78 | 142.60B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
369.25 | 141.45B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.04 | 123.83B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.65 | 43.07B | 5.69B | 1.41B | 577.90M | 6.9828 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-08-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Iniziato | Stephens | Overweight |
| 2023-11-29 | Iniziato | Craig Hallum | Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-24 | Iniziato | BTIG Research | Buy |
| 2021-08-24 | Iniziato | Cowen | Outperform |
| 2021-08-24 | Iniziato | Stephens | Overweight |
| 2021-08-24 | Iniziato | Stifel | Buy |
| 2021-08-24 | Iniziato | Wedbush | Outperform |
| 2021-08-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Maxcyte Inc Borsa (MXCT) Ultime notizie
Is MaxCyte Inc. stock a buy in volatile markets2025 Risk Factors & Free Safe Entry Trade Signal Reports - newser.com
Predicting MaxCyte Inc. trend using moving averages2025 Breakouts & Breakdowns & Intraday High Probability Alerts - newser.com
What dividend safety rating applies to MaxCyte Inc. (MYE0) stockJuly 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
Why MaxCyte Inc. stock remains a top recommendation2025 Key Lessons & Long-Term Capital Growth Strategies - newser.com
Is MaxCyte Inc. trending in predictive chart modelsMarket Performance Report & Verified Stock Trade Ideas - newser.com
Will MaxCyte Inc. stock recover faster than peers2025 Earnings Impact & Daily Volume Surge Trade Alerts - newser.com
MaxCyte cuts 15% of global workforce, boosts core revenue guidance - MSN
MaxCyte announces 34% workforce reduction to cut costs - MSN
Will MaxCyte Inc. (MYE0) stock deliver stable dividendsRate Cut & Low Risk Growth Stock Ideas - newser.com
MaxCyte Inc. recovery potential after sell offPortfolio Profit Report & Daily Chart Pattern Signal Reports - newser.com
Real time social sentiment graph for MaxCyte Inc.Quarterly Performance Summary & Daily Chart Pattern Signals - newser.com
Farther Finance Advisors LLC Raises Holdings in MaxCyte, Inc. $MXCT - Defense World
Is this a good reentry point in MaxCyte Inc.July 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Will MaxCyte Inc. (MYE0) stock see valuation expansion2025 Volume Leaders & Long-Term Growth Stock Strategies - newser.com
Applying big data sentiment scoring on MaxCyte Inc.July 2025 Sector Moves & Free Safe Capital Growth Stock Tips - newser.com
Market reaction to MaxCyte Inc.’s recent news2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Applying sector rotation models to MaxCyte Inc.July 2025 PreEarnings & Weekly Breakout Opportunity Watchlist - newser.com
How to use a screener to detect MaxCyte Inc. breakoutsJuly 2025 Update & High Accuracy Trade Alerts - newser.com
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 - The Manila Times
Q3 2025 Results on Nov 5 — MaxCyte to Release Financials After U.S. Market Close; Call 4:30 PM ET - Stock Titan
MaxCyte, Inc. Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - MarketScreener
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - The Manila Times
Oklahoma City NewsThe Oklahoman - FinancialContent
Can MaxCyte Inc. stock deliver sustainable ROEQuarterly Market Summary & Reliable Breakout Forecasts - newser.com
MaxCyte Signs Strategic Platform License with Moonlight Bio | MXCT Stock News - Stock Titan
Intraday pattern recognizer results for MaxCyte Inc.Short Setup & Verified Swing Trading Watchlists - newser.com
MaxCyte, Inc. (NASDAQ:MXCT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
What analysts say about MaxCyte Inc stockTrade Execution Strategies & The Best Picks Hiding in Plain Sight - earlytimes.in
Tick level data insight on MaxCyte Inc. volatilityJuly 2025 Levels & Weekly High Conviction Ideas - newser.com
Automated trading signals detected on MaxCyte Inc.Weekly Profit Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Maxcyte Inc Azioni (MXCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Maxcyte Inc Azioni (MXCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
1.23%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):